Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ricardo Nalda‐Molina"'
Publikováno v:
Biomedicines, Vol 11, Iss 10, p 2822 (2023)
Adalimumab is a fully human monoclonal antibody used for the treatment of inflammatory bowel disease (IBD). Due to its considerably variable pharmacokinetics and the risk of developing antibodies against adalimumab, it is highly recommended to use a
Externí odkaz:
https://doaj.org/article/1e88d5b9b68f4280ba6d182b47a4f340
Autor:
Antonio Franco, Patricio Más-Serrano, Noelia Balibrea, David Rodriguez, Aurora Javaloyes, Marcos Díaz, Isabel Gascón, Amelia Ramon-Lopez, Javier Perez-Contreras, Juan Selva, Ricardo Nalda-Molina
Publikováno v:
Nefrología, Vol 39, Iss 5, Pp 506-512 (2019)
Resumen: El objetivo del presente estudio fue evaluar las concentraciones valle (Cpvalle) y la pauta posológica de tacrolimus tras la conversión de Prograf o Advagraf a Envarsus (nueva forma farmacéutica con tecnología Meltdose que mejora la abso
Externí odkaz:
https://doaj.org/article/1b48f1b35979460691cef97f0caf4677
Autor:
Antonio Franco, Patricio Más-Serrano, Noelia Balibrea, David Rodriguez, Aurora Javaloyes, Marcos Díaz, Isabel Gascón, Amelia Ramon-Lopez, Javier Perez-Contreras, Juan Selva, Ricardo Nalda-Molina
Publikováno v:
Nefrología (English Edition), Vol 39, Iss 5, Pp 506-512 (2019)
The aim of this study was to evaluate the trough concentrations (Cptrough) and the tacrolimus dosage regimen after the conversion of Prograf or Advagraf to Envarsus (new pharmaceutical form with MeltDose technology that improves the absorption of fat
Externí odkaz:
https://doaj.org/article/f5738a702a174f7d839e1d1a274a5186
Autor:
Silvia Marquez-Megias, Ricardo Nalda-Molina, Javier Sanz-Valero, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix, Amelia Ramon-Lopez
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 1009 (2022)
Infliximab and adalimumab are monoclonal antibodies against tumor necrosis factor (anti-TNF) used to manage inflammatory bowel disease (IBD). Therapeutic Drug Monitoring (TDM) has been proven to prevent immunogenicity, to achieve better long-term cli
Externí odkaz:
https://doaj.org/article/5841c17584e24b508b4196d38b054d01
Autor:
Efthymios Neroutsos, Ricardo Nalda-Molina, Anna Paisiou, Kalliopi Zisaki, Evgenios Goussetis, Alexandros Spyridonidis, Vasiliki Kitra, Stelios Grafakos, Georgia Valsami, Aristides Dokoumetzidis
Publikováno v:
Pharmaceutics, Vol 14, Iss 3, p 647 (2022)
We develop a population pharmacokinetic model to describe Busulfan pharmacokinetics in paediatric patients and investigate by simulations the impact of various sampling schedules on the calculation of AUC. Seventy-six children had 2 h infusions every
Externí odkaz:
https://doaj.org/article/bdba15ffde1540cf8b859651813054a0
Autor:
Silvia Marquez-Megias, Amelia Ramon-Lopez, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix, Ricardo Nalda-Molina
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1244 (2021)
Adalimumab is a monoclonal antibody used for inflammatory bowel disease. Due to its considerably variable pharmacokinetics, the loss of response and the development of anti-antibodies, it is highly recommended to use a model-informed precision dosing
Externí odkaz:
https://doaj.org/article/3dcfc7e0b92e4f6ca403a062ca3cdc7a
Autor:
María Remedios, Candela-Boix, Amelia, Ramón-López, Ricardo, Nalda-Molina, Marcos, Díaz-González, Silvia, Márquez-Megías, Patricio, Más-Serrano
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 45(7)
Sirolimus is used in the immunosuppressive therapeutic treatment of kidney transplant patients. The high pharmacokinetic variability of sirolimus makes pharmacokinetic monitoring and dosage individualization of mmunosuppressive therapy a key process
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::befcbcbc02ad45cd62d81bf9cd1e584d
https://pubmed.ncbi.nlm.nih.gov/35379113
https://pubmed.ncbi.nlm.nih.gov/35379113
Autor:
Isabel Gascón, Amelia Ramon-Lopez, Javier Perez-Contreras, Juan Selva, Ricardo Nalda-Molina, Patricio Más-Serrano, Marcos Díaz, Noelia Balibrea, David Jiménez Rodríguez, Aurora Javaloyes, Antonio Franco
Publikováno v:
Nefrología, Vol 39, Iss 5, Pp 506-512 (2019)
Resumen: El objetivo del presente estudio fue evaluar las concentraciones valle (Cpvalle) y la pauta posológica de tacrolimus tras la conversión de Prograf o Advagraf a Envarsus (nueva forma farmacéutica con tecnología Meltdose que mejora la abso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a370b0fabd5d0649146bdf1fe6f1c6
https://doi.org/10.1016/j.nefro.2018.11.009
https://doi.org/10.1016/j.nefro.2018.11.009
Autor:
Noelia Balibrea, Antonio Franco, Amelia Ramon-Lopez, Ricardo Nalda-Molina, Aurora Javaloyes, Isabel Gascón, David Jiménez Rodríguez, Patricio Más-Serrano, Marcos Díaz, Javier Perez-Contreras, Juan Selva
Publikováno v:
Nefrología (English Edition), Vol 39, Iss 5, Pp 506-512 (2019)
The aim of this study was to evaluate the trough concentrations (Cptrough) and the tacrolimus dosage regimen after the conversion of Prograf or Advagraf to Envarsus (new pharmaceutical form with MeltDose technology that improves the absorption of fat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4e4f2c2e11c6d1acb0de6950d42e8a
http://www.sciencedirect.com/science/article/pii/S2013251419301397
http://www.sciencedirect.com/science/article/pii/S2013251419301397
Autor:
S Marquez-Megías, C Colomer, J Selva, M Díaz-González, Amelia Ramon-Lopez, Ricardo Nalda-Molina, A Gutiérrez, P Mas-Serrano
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Adalimumab is an anti-TNFα monoclonal antibody used in inflammatory bowel disease (IBD). Its efficacy can benefit from therapeutic drug monitoring (TDM). However, because there are several population pharmacokinetic models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::849c419185936068d339ea9e9f8f87e8
https://doi.org/10.1136/ejhpharm-2020-eahpconf.284
https://doi.org/10.1136/ejhpharm-2020-eahpconf.284